ARVO

Elias Kahan, MD, speaks about wide-field contact specular microscopy and the expanding scope of corneal endothelial research.

Pucker shares topline results from a study that investigated the difference in meibomobian gland morphology when measured with a Visante OCT versus an OCULUS Keratograph 5M

Voretigene neparvovec (Luxturna, Spark Therapeutics, Inc.) was shown to be safe and effective in real-world settings.

Huntington's disease (HD) is an autosomal-dominant, fully-penetrant, neurodegenerative disease that most commonly affects adults during middle age.

In a conversation with the Eye Care Network at ARVO, Osamah Saeedi, MD, MS, Associate Professor of Ophthalmology, Director of Clinical Research and Director of the Glaucoma Division at the University of Maryland School of Medicine, explained the key findings from his poster.

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

Dustin Morley, PhD, principal research scientist at LENSAR, discusses research on applying deep learning to benefit FLACS procedures.

Sadda discusses his goals for ARVO, focusing on enhancing the organization's role in promoting scientific exchange in vision research. He underscores the significance of the annual meetings for networking and driving innovation in ophthalmology.

In a conversation with the Eye Care Network at ARVO, Corradetti, a research scientist at Doheny Eye Institute, explained the key findings from her work.

Four poster presentations at the Association for Research in Vision and Ophthalmology’s (ARVO) 2024 Annual Meeting in Seattle, Washington, demonstrate the possibilities.

Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.

John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. The children with CVI underwent a complete pediatric neuro-ophthalmologic examination.

Cynthia Roberts, PhD, sat down to discuss a 5-year prospective study to compare ocular stiffness parameters in, diabetes with retinopathy, diabetes without retinopathy, and normal subjects at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

A quartet of studies presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting addressed diverse retina-related challenges and unveiled findings with the potential to revolutionize vision science.

Antonio Filipe Macedo, OD, MSc, PhD, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about vision-related activity difficulties in people diagnosed with neovascular age-related macular degeneration (nAMD)and vision impairment.

In a presentation at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, researchers used Google’s recommended top 8 uveitis patient educational websites in the study to determine whether ChatGPT 4.0 could be used as a uveitis patient online resource.

The investigators conducted a retrospective chart review of patients’ demographic and clinical data from 2005 to 2020.

At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.

At this year's ARVO meeting, Paolo Silva, MD, presented data on Protocol AA on behalf of the DRCR Retina Network and the effect of diabetic retinopathy lesion location and severity on the risk for progression in the long term.

In this investigation, the second stage of the CHAMP phase 3 trial assessed the impact of prolonging drug administration for an extra 12 months on myopia control and the occurrence of myopia rebound upon cessation of dosing.

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Research being presented at the Association for Research in Vision and Ophthalmology’s 2024 Annual Meeting in Seattle, Washington, is examining novel interventions that could address the growth in myopia.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.